| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5630260 | Journal of Neuroimmunology | 2017 | 4 Pages |
â¢The prognostic involvement of CHI3L1 in clinically isolated syndromes is further studied.â¢Serum CHI3L1 levels are increased by the effect of glatiramer acetate treatment.â¢Non-responder patients to interferon-beta treatment have increased serum CHI3L1 levels.â¢Results may suggest a role for CHI3L1 as an interferon-beta treatment response biomarker in RRMS patients.
Chitinase 3-like 1 (CHI3L1) plays a prognostic role in patients with multiple sclerosis (MS). Here, we investigated a potential association between CHI3L1 and the response to interferon-beta (IFNβ) and glatiramer acetate (GA). Serum CHI3L1 levels were measured by ELISA in 117 relapsing-remitting MS (RRMS) patients, 76 IFNβ-treated and 41 GA-treated patients. CHI3L1 levels were increased by GA (p = 0.014) but unchanged by IFNβ (p = 0.830). CHI3L1 was associated with IFNβ response and levels were higher in non-responder group (p = 0.020), while GA showed no responder effect (p = 0.943). These results suggest a role for CHI3L1 as response biomarker to IFNβ in RRMS patients.
Graphical abstract.Download high-res image (97KB)Download full-size image
